AI assistant
MAXCYTE, INC. Director's Dealing 2021
10520_sha_2021-08-10_9033e811-b443-4570-b7af-2f3ab90db4a8.html
Director's Dealing
Open in viewerOpens in your device viewer
{# SEO P0-1: filing HTML is rendered server-side so Googlebot
sees the full text without executing JS or following an
iframe to a Disallow'd CDN path. The content has already
been sanitized through filings.seo.sanitize_filing_html. #}
National Storage Mechanism | Additional information 
RNS Number : 0791I
MaxCyte, Inc.
10 August 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
Gaithersburg, Maryland - 10 August 2021: MaxCyte (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, announces that on 9 August 2021, options of common stock in the Company ("Common Stock") were granted equally to all Company employees, including 100,000 options granted to PDMRs who are directors or officers of the Company ("PDMR Option Grants"). Details of the PDMR Option Grants are given below:
| Grants to PDMRs | |
| Doerfler, Doug | 10,000 |
| Thompson, J. Stark | 10,000 |
| Mandell, Art | 10,000 |
| Erck, Stan | 10,000 |
| Brooke, Will | 10,000 |
| Johnston, John | 10,000 |
| Douglas, Richard | 10,000 |
| Hemrajani, Rekha | 10,000 |
| Al-Wakeel, Yasir | 10,000 |
| Murphy, Amanda | 10,000 |
| Total | 100,000 |
All option grants vest over 4 years. 1/4th of the grants vest 1 year following the date of the grant, with the remainder of the options vesting ratably monthly in 36 monthly installments thereafter. The options have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 9 August 2021, of $16.63
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Doug Doerfler | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Director | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte, Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Options of Common Stock | |
| b) | Identification Code | US57777K1060 | |
| c) | Nature of the transaction | Grant of options | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A $16.63 |
10,000 options | ||
| e) | Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
| f) | Date of the transaction | 9 August 2021 | |
| g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | J. Stark Thompson | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chairman | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte, Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Options of Common Stock | |
| b) | Identification Code | US57777K1060 | |
| c) | Nature of the transaction | Grant of options | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A $16.63 |
10,000 options | ||
| e) | Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
| f) | Date of the transaction | 9 August 2021 | |
| g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Art Mandell | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte, Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Options of Common Stock | |
| b) | Identification Code | US57777K1060 | |
| c) | Nature of the transaction | Grant of options | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A $16.63 |
10,000 options | ||
| e) | Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
| f) | Date of the transaction | 9 August 2021 | |
| g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Stan Erck | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte, Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Options of Common Stock | |
| b) | Identification Code | US57777K1060 | |
| c) | Nature of the transaction | Grant of options | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A $16.63 |
10,000 options | ||
| e) | Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
| f) | Date of the transaction | 9 August 2021 | |
| g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Will Brooke | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte, Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Options of Common Stock | |
| b) | Identification Code | US57777K1060 | |
| c) | Nature of the transaction | Grant of options | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A $16.63 |
10,000 options | ||
| e) | Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
| f) | Date of the transaction | 9 August 2021 | |
| g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | John Johnston | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte, Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Options of Common Stock | |
| b) | Identification Code | US57777K1060 | |
| c) | Nature of the transaction | Grant of options | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A $16.63 |
10,000 options | ||
| e) | Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
| f) | Date of the transaction | 9 August 2021 | |
| g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Richard Douglas | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte, Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Options of Common Stock | |
| b) | Identification Code | US57777K1060 | |
| c) | Nature of the transaction | Grant of options | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A $16.63 |
10,000 options | ||
| e) | Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
| f) | Date of the transaction | 9 August 2021 | |
| g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Rekha Hemrajani | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte, Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Options of Common Stock | |
| b) | Identification Code | US57777K1060 | |
| c) | Nature of the transaction | Grant of options | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A $16.63 |
10,000 options | ||
| e) | Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
| f) | Date of the transaction | 9 August 2021 | |
| g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Yasir Al-Wakeel | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte, Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Options of Common Stock | |
| b) | Identification Code | US57777K1060 | |
| c) | Nature of the transaction | Grant of options | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A $16.63 |
10,000 options | ||
| e) | Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
| f) | Date of the transaction | 9 August 2021 | |
| g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Amanda Murphy | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | MaxCyte, Inc. | |
| b) | LEI | 54930053YHXULRFCU991 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Options of Common Stock | |
| b) | Identification Code | US57777K1060 | |
| c) | Nature of the transaction | Grant of options | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| N/A $16.63 |
10,000 options | ||
| e) | Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
| f) | Date of the transaction | 9 August 2021 | |
| g) | Place of the transaction | London Stock Exchange, AIM Market (XLON) |
MaxCyte Contacts:
| MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer |
+1 301-944-1660 |
| Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden |
+44 (0)20 7886 2500 |
| Joint Corporate Broker Numis Securities Limited James Black / Duncan Monteith / Matthew O'Dowd |
+44 (0)20 7260 1000 |
| Joint Corporate Broker Stifel Nicolaus Europe Limited Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams |
+44 (0)20 7710 7600 |
| UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh |
+44 (0)203 709 5700 [email protected] |
| US IR Adviser Gilmartin Group David Deuchler, CFA |
+1 415-937-5400 [email protected] |
| US Media Relations Jamie Lacey-Moreira PressComm PR, LLC |
+1 410-299-3310 [email protected] |
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEAFPNELEFEAA